Answers are grounded in this paper and cite their sources.
Survey study shows varied dosing patterns of CDK4/6 inhibitors in older metastatic breast cancer patients, suggesting a need for tailored approaches.
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) improve outcomes in HR+/HER2− metastatic breast cancer (MBC) [1–5]. However, older adults remain underrepresented in pivotal trials [6]. Although available evidence indicates that older patients benefit from CDK4/6i, higher toxicity and treatment discontinuation rates have been documented [7,8]. Guidelines do not recommend age- or frailty-based initial dose adjustments, leaving oncologists to individualize treatment without prospective evidence.
No takes yet. Share an insight, caveat, or question.
Schiza et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: